News Archive

Nivolumab

MHRA authorises cancer treatment variation with an administration time of 3–5 minutes

MHRA authorises cancer treatment variation with an administration time of 3–5 minutes

Featured| MHRA| Nivolumab| under the skin injection

On 30 April 2025, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved a new under-the-skin ...

Cabo + nivo & ipi delays kidney cancer progression

Cabo + nivo & ipi delays kidney cancer progression

Cabozantinib| Ipilimumab| Nivolumab

Adding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival ...

Kidney Cancer UK represents patients at NICE nivo+ipi appraisal

Kidney Cancer UK represents patients at NICE nivo+ipi appraisal

Ipilimumab| NICE| Nivolumab

On 3rd February 2022, NICE approve the use of nivolumab with ipilimumab as a first line treatment for kidney ...

No results found.